Sonja Nelson - 05 Jul 2023 Form 4 Insider Report for Ambrx Biopharma Inc.

Role
Chief Financial Officer
Signature
/s/ Sonja Nelson
Issuer symbol
N/A
Transactions as of
05 Jul 2023
Net transactions value
$0
Form type
4
Filing time
07 Jul 2023, 16:05:51 UTC
Previous filing
28 Apr 2023
Next filing
31 Oct 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AMAM Stock Option (right to buy) Award $0 +389,000 $0.000000 389,000 05 Jul 2023 Ordinary Shares 389,000 $2.38 Direct F1, F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The options will have an exercise price per share equal to the fair market value per ordinary share on the grant date based on the trading price of the Issuer's American Depositary Shares ("ADSs").
F2 1/6 of the Ordinary Shares subject to the option vest on January 5, 2024, and the remainder vests in ten (10) equal quarterly installments following such date.
F3 The Ordinary Shares of the Issuer may be represented by ADSs. Each ADS represents seven Ordinary Shares of the Issuer.